Saxenda Trial: Every Trial, Results in Plain English
The biggest average Saxenda trial weight loss findings: 7.4% on liraglutide 3.0 mg daily in SCALE Obesity and Prediabetes, against 3% on placebo.
- Major trials here
- 1
- Top average loss
- 7.4%
- Placebo, same trial
- 3%
Saxenda in brief
Its half-life is about 13 hours: after 13 h half is gone, and after five half-lives (2.7 d) about 3% is left.
For SCALE Obesity and Prediabetes, 56 weeks: weight loss was 7.4% of body weight, versus 3% on placebo.
Sources: FDA label on DailyMed.
Every trial in one table
Clicking a trial name opens its ClinicalTrials.gov record.
| Trial | Who was in it | People | Weeks | Compared with | Main result | In the label as | NCT number |
|---|---|---|---|---|---|---|---|
| SCALE Obesity and Prediabetes | Participants were adults with obesity or overweight and no type 2 diabetes | 3,731 | 56 | placebo | 7.4% weight lost | Study 1 in the Saxenda label | NCT01272219 |
Sources: PubMed.
Saxenda trial weight loss findings
The average share of body weight lost by the end of each trial. Each trial enrolled a different group of people, so compare doses within a single trial first.
| Trial | Dose group | Average weight lost | Placebo or comparison | Weeks | Who was in it |
|---|---|---|---|---|---|
| SCALE Obesity and Prediabetes | Liraglutide 3.0 mg daily | 7.4% | 3% | 56 | Participants were adults with obesity or overweight and no type 2 diabetes |
Source of the label: SCALE Obesity and Prediabetes (FDA label (DailyMed)).
Safety signals
| Trial | Dose group | What happened | Drug | Placebo |
|---|---|---|---|---|
| SCALE Obesity and Prediabetes | All doses, label pool | Stopped for side effects | 9.8% | Not listed |
Sources: FDA label on DailyMed.
The Saxenda label warns about these serious risks:
- A boxed warning concerns Thyroid C-cell tumors. In rodents, it led to Thyroid C-cell tumors. Whether it causes these tumors in people is not known. You must not use it if you have MEN 2 or if you or a family member has a history of medullary thyroid cancer (MTC).
- Inflammation of the pancreas. This medicine can cause the pancreas to become inflamed Stop taking it if severe stomach pain sometimes spreads to your back and does not go away. Get medical help.
- Gallbladder disease. You can get gallstones and inflammation of the gallbladder. Report upper-right belly pain, fever, or yellow skin or eyes.
- Low blood sugar. The risk of low blood sugar is higher when you take it with insulin or a sulfonylurea. Those medicine doses may need lowering.
- Faster heart rate. Can raise resting heart rate. Let your doctor know if your heartbeat races or pounds while you are at rest.
- Fluid loss can lead to kidney injury. Fluid loss from vomiting or diarrhea can lead to kidney injury. Report heavy fluid loss, and drink fluids.
Source: FDA label (DailyMed).
Source: FDA label (DailyMed).
Trials for liraglutide that are recruiting now
Find liraglutide trials that are recruiting on ClinicalTrials.gov. Choose your state filter first. Next, ask the study team about travel and about costs.